AbCellera (ABCL) Stock Pops 6% as Menopause Drug Hits Phase 2 Finish Line

AbCellera (ABCL) stock rose 6.13% with an intraday jump of 10.3% to $6.53 after Q2 earnings and pipeline news. Top-line Phase 2 results for ABCL635, a non-hormonal menopause treatment, will be released before market open on August 10. Q2 revenue fell 76.3% year-over-year to $4.05 million, while net loss widened to $55.4 million.